{"entity": "researcher", "timestamp": "2026-08-22T07:49:21.003Z", "family": "Hu", "given": "Yang", "initials": "Y", "orcid": "0000-0002-8702-6654", "affiliations": ["Translational PKPD Group, Department of Pharmaceutical Biosciences, Associate Member of SciLifeLab, Uppsala University, Uppsala, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/bd6b24b1fddd42839186695c2920a747.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/bd6b24b1fddd42839186695c2920a747"}}, "publications": [{"entity": "publication", "iuid": "45a835498fbf41c390d679c484b568f2", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/45a835498fbf41c390d679c484b568f2.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/45a835498fbf41c390d679c484b568f2"}}, "title": "Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis.", "authors": [{"family": "Andronis", "given": "Christos", "initials": "C", "orcid": "0000-0002-6174-579X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1d39bce1ca65415e84d55eb343195110.json"}}, {"family": "Silva", "given": "Jo\u00e3o Pedro", "initials": "JP", "orcid": "0000-0002-5656-0897", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cbd2157630cf4708a232260c31918a51.json"}}, {"family": "Lekka", "given": "Eftychia", "initials": "E", "orcid": "0000-0003-4416-0148", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0c3fe371999d4b908c7f1ae1de76c3b9.json"}}, {"family": "Virvilis", "given": "Vassilis", "initials": "V", "orcid": "0000-0003-4573-0501", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9659ff042e9c4c93b72ddea6dbf9d9ec.json"}}, {"family": "Carmo", "given": "Helena", "initials": "H", "orcid": "0000-0002-6650-5285", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/abbb69a5302b45a0824a030ada78c389.json"}}, {"family": "Bampali", "given": "Konstantina", "initials": "K", "orcid": "0000-0001-5063-4675", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/5f53bde26287414e871556bce7d6f44f.json"}}, {"family": "Ernst", "given": "Margot", "initials": "M", "orcid": "0000-0002-9809-2649", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/5d0ef853c1af4955b30e7f2e7ba45745.json"}}, {"family": "Hu", "given": "Yang", "initials": "Y", "orcid": "0000-0002-8702-6654", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/bd6b24b1fddd42839186695c2920a747.json"}}, {"family": "Loryan", "given": "Irena", "initials": "I", "orcid": "0000-0002-1557-4416", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8373a9e8e10a48b7904075577f7a15e6.json"}}, {"family": "Richard", "given": "Jacques", "initials": "J", "orcid": "0000-0002-5286-9088", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/08240fcf3bc04e4dbd9326a40448b167.json"}}, {"family": "Carvalho", "given": "F\u00e9lix", "initials": "F", "orcid": "0000-0003-3858-3494", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4ba8f1d5c4854156b0270667e8edcdc7.json"}}, {"family": "Savi\u0107", "given": "Miroslav M", "initials": "MM", "orcid": "0000-0002-6934-9193", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f8c93c91a41a460183cc585a1eb63447.json"}}], "type": "journal article", "published": "2020-08-00", "journal": {"title": "Arch. Toxicol.", "issn": "1432-0738", "volume": "94", "issue": "8", "pages": "2829-2845", "issn-l": "0340-5761"}, "abstract": "Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and elucidate potential biological mechanisms of action frequently associated with MCAEs, we present a unique workflow linking observational population data with the available knowledge at molecular, cellular, and psychopharmacology levels. It is based on statistical analysis of pharmacovigilance reports and subsequent signaling pathway analyses, followed by evidence-based expert manual curation of the outcomes. Our analysis: (a) ranked pharmaceuticals with high occurrence of such adverse events (AEs), based on disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database, and (b) identified 120 associated genes and common pathway nodes possibly underlying MCAEs. Nearly two-thirds of the identified genes were related to immune modulation, which supports the critical involvement of immune cells and their responses in the regulation of the central nervous system function. This finding also means that pharmaceuticals with a negligible central nervous system exposure may induce MCAEs through dysregulation of the peripheral immune system. Knowledge gained through this workflow unravels putative hallmark biological targets and mediators of drug-induced mood and cognitive disorders that need to be further assessed and validated in experimental models. Thereafter, they can be used to substantially improve in silico/in vitro/in vivo tools for predicting these adversities at a preclinical stage.", "doi": "10.1007/s00204-020-02788-1", "pmid": "32504122", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7395038"}, {"db": "pii", "key": "10.1007/s00204-020-02788-1"}], "notes": [], "created": "2026-08-21T11:05:56.904Z", "modified": "2026-08-21T11:05:57.410Z"}, {"entity": "publication", "iuid": "08f46c6228724976a73b265e635992ec", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/08f46c6228724976a73b265e635992ec.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/08f46c6228724976a73b265e635992ec"}}, "title": "In Vivo Quantitative Understanding of PEGylated Liposome's Influence on Brain Delivery of Diphenhydramine.", "authors": [{"family": "Hu", "given": "Yang", "initials": "Y", "orcid": "0000-0002-8702-6654", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/bd6b24b1fddd42839186695c2920a747.json"}}, {"family": "Gaillard", "given": "Pieter J", "initials": "PJ"}, {"family": "Rip", "given": "Jaap", "initials": "J"}, {"family": "de Lange", "given": "Elizabeth C M", "initials": "ECM"}, {"family": "Hammarlund-Udenaes", "given": "Margareta", "initials": "M"}], "type": "journal article", "published": "2018-12-03", "journal": {"title": "Mol. Pharm.", "issn": "1543-8392", "volume": "15", "issue": "12", "pages": "5493-5500", "issn-l": "1543-8384"}, "abstract": "Despite the promising features of liposomes as brain drug delivery vehicles, it remains uncertain how they influence the brain uptake in vivo. In order to gain a better fundamental understanding of the interaction between liposomes and the blood-brain barrier (BBB), it is indispensable to test if liposomes affect drugs with different BBB transport properties (active influx or efflux) differently. The aim of this study was to quantitatively evaluate how PEGylated (PEG) liposomes influence brain delivery of diphenhydramine (DPH), a drug with active influx at the BBB, in rats. The brain uptake of DPH after 30 min intravenous infusion of free DPH, PEG liposomal DPH, or free DPH + empty PEG liposomes was compared by determining the unbound DPH concentrations in brain interstitial fluid and plasma with microdialysis. Regular blood samples were taken to measure total DPH concentrations in plasma. Free DPH was actively taken up into the brain time-dependently, with higher uptake at early time points followed by an unbound brain-to-plasma exposure ratio ( Kp,uu) of 3.0. The encapsulation in PEG liposomes significantly decreased brain uptake of DPH, with a reduction of Kp,uu to 1.5 ( p < 0.05). When empty PEG liposomes were coadministered with free drug, DPH brain uptake had a tendency to decrease ( Kp,uu 2.3), and DPH was found to bind to the liposomes. This study showed that PEG liposomes decreased the brain delivery of DPH in a complex manner, contributing to the understanding of the intricate interactions between drug, liposomes, and the BBB.", "doi": "10.1021/acs.molpharmaceut.8b00611", "pmid": "30376346", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-21T11:34:15.823Z", "modified": "2026-08-21T11:34:15.847Z"}]}